A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02443324 |
Recruitment Status :
Completed
First Posted : May 13, 2015
Last Update Posted : August 18, 2022
|
Sponsor:
Eli Lilly and Company
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | August 31, 2018 |
Actual Study Completion Date : | April 12, 2022 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
March 31, 2023 | January 10, 2024 |
2 |
February 19, 2024 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):